INDIA IPO
  • Home
  • About
    • About us
    • Our CSR
  • Services

    IPO

    • Initial Public Offering (IPO)
    • SME IPO Consultation
    • Mainline IPO Consultation
    • Follow-On Public Offer (FPO)
    • Pre-IPO Funding Consultants

    Capital Raising

    • Social Stock Exchange
    • Private Placement
    • Project Funding
    • REIT
    • SM REIT
    • Rights Issue Advisory
    • InvIT Rights Issue
    • InvIT Public Issue
    • InvIT Private Issue
    • Debt Syndication
    • Securitised Debt Instruments
    • Public Municipal Debt
    • Private Municipal Debt

    Finance Advisory

    • Business Valuation
    • Corporate Finance
    • Financial Modelling
    • Project Finance
  • Investors
  • Merchant Bankers

    SME

    • List of SME Merchant Bankers

    MAINBOARD

    • List of Mainboard Merchant Bankers
  • Resources

    Reports

    • Daily Reporter
    • IPO Calendar
    • Upcoming IPO Calendar
    • Mainline IPO Report
    • SME IPO Report
    • SME IPOs by Sector
    • Mainboard IPOs by Sector

    IPO Knowledge

    • IPO World Magazine
    • IPO Process
    • Pre-IPO Process Guidance
    • IPO Blogs
    • Sector Wise IPO List In India
    • List of IPO Registrar

    Notifications / Circulars

    • SEBI ICDR Amendment Regulations 10.03.2025
    • SEBI SME IPO ICDR Amendments report 10.03.25
    • ICDR
    • BSE SME Eligibility Criteria
    • NSE Emerge Eligibility Criteria
  • News/Updates
    • Markets & Money Update
    • IPO & Market Snaps
  • Contact Us
  • Check IPO Feasibility
Check IPO Feasibility
INDIA IPO
INDIA IPO

Contact Info:

  • +91-96506-37280
  • +011-47008280
  • info@indiaipo.in
  • 808, 8thFloor D-Mall, Netaji Subhash Place, Pitampura, Delhi-110034.
shape
  1. Home
  2. News
  3. Suven Life Sciences Board Approves ₹425.70 Crore Warrant Conversion
ipo services in India
India IPO
  • 06 Mar 2026
  • X
 Suven Life Sciences Board Approves ₹425.70 Crore Warrant Conversion

Suven Life Sciences Limited's Board of Directors formally approved the conversion of 3,17,68,764 warrants into equity shares at ₹134 per share during their meeting on March 6, 2026. The allotment to promoter group entity JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED raised ₹425.70 crore and increased the company's paid-up equity capital from ₹23.19 crore to ₹26.37 crore, demonstrating strong promoter confidence and providing enhanced financial resources for strategic growth.

Suven Life Sciences Board Approves ₹425.70 Crore Warrant Conversion

Suven Life Sciences Limited's Board of Directors has formally approved the conversion of warrants into equity shares, completing a significant capital raising exercise. The board meeting held on March 6, 2026, resulted in the allotment of equity shares to a promoter group entity, strengthening the company's financial position. Board Meeting Outcome The Board of Directors meeting, which commenced at 11:00 AM IST and concluded at 11:20 AM IST on March 6, 2026, approved the conversion of fully paid warrants into equity shares. The conversion was executed in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Parameter: Details Meeting Date: March 6, 2026 Warrants Converted: 3,17,68,764 Issue Price: ₹134 per share Total Consideration: ₹425,70,14,376 Allotment Details The company has allotted 3,17,68,764 equity shares of ₹1 each to JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED in its capacity as sole trustee of Jasti Family Trust. This promoter group entity has provided 100% consideration amount aggregating to ₹425,70,14,376 in compliance with regulatory requirements. Allottee: Shares Allotted JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED: 3,17,68,764 (As sole trustee of Jasti Family Trust): Capital Structure Impact The warrant conversion has resulted in a significant expansion of the company's equity base. The paid-up equity share capital has increased substantially following the allotment. Capital Structure: Before Allotment After Allotment Equity Shares: 23,19,51,819 26,37,20,583 Amount (₹): 23,19,51,819.00 26,37,20,583.00 Regulatory Compliance The allotment was conducted as a preferential issue in accordance with Chapter V of the SEBI (ICDR) Regulations, 2018. The company has fulfilled all disclosure requirements pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring complete transparency in the process. This successful warrant conversion demonstrates strong promoter confidence and provides Suven Life Sciences with enhanced financial resources to pursue its strategic objectives in the pharmaceutical sector. Suven Life Sciences Limited has issued a formal clarification to BSE Limited addressing recent price movements in its stock. The communication, dated February 6, 2026, was submitted in response to BSE's surveillance inquiry regarding unusual price activity. Company's Response to BSE Surveillance The pharmaceutical company clarified its position through a detailed response to BSE's surveillance department. The clarification was prompted by BSE's inquiry reference L/SURV/ONL/PV/AJ/ 2025-2026 / 3355 dated February 5, 2026. Parameter Details Communication Date February 6, 2026 BSE Scrip Code 530239 Reference Number L/SURV/ONL/PV/AJ/ 2025-2026 / 3355 Signatory K. Sangeetha Laxmi, Company Secretary Regulatory Compliance Statement Suven Life Sciences emphasized its commitment to regulatory compliance, stating that the company has been consistently notifying stock exchanges of all material events and information falling under Regulation 30 of SEBI (LODR) Regulations, 2015. The company maintained that it follows proper disclosure protocols for all significant developments. The management confirmed that no material announcements or events are currently pending notification to stock exchanges under SEBI regulations that could influence the stock's price or volume behavior. Market Speculation Attribution The company attributed recent price and volume movements to market speculation rather than any undisclosed material information. Suven Life Sciences stated it has no additional comments regarding the recent market developments affecting its stock performance. The clarification has been made available to the general public through dissemination on BSE's website and the company's official website, ensuring transparency in communication with stakeholders. We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better. Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians. As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

Recent News

Groww Allots 10 Crore Equity Shares to Employee Welfare Trust Under ESOP Scheme
groww-allots-10-crore-equity-shares-to-employee-welfare-trus...
06 Mar 2026
Global Investors Retreat Amid Middle East Tensions
global-investors-retreat-amid-middle-east-tensions
06 Mar 2026
Shriram Finance Records Rs. 138.88 Crore Block Trade on NSE
shriram-finance-records-rs-13888-crore-block-trade-on-nse
06 Mar 2026
backed incubator SINE to fetch Rs 55 crore in SEDEMAC Mechatronics IPO
backed-incubator-sine-to-fetch-rs-55-crore-in-sedemac-mechat...
06 Mar 2026
IIT Bombay to reap Rs 55 crore windfall as Sedemac IPO to unlock nearly Rs 4,800 crore
iit-bombay-to-reap-rs-55-crore-windfall-as-sedemac-ipo-to-un...
06 Mar 2026
Pramerica Launches Rising Bharat Fund Targeting Midcap Growth
pramerica-launches-rising-bharat-fund-targeting-midcap-growt...
06 Mar 2026
Women cut FD exposure from 45% to 20%, raise equity MF share to 32%: report
women-cut-fd-exposure-from-45-to-20-raise-equity-mf-share-to...
06 Mar 2026
Nifty’s primary trend still bearish, 24,300 key level to watch: Vinay Rajani
niftys-primary-trend-still-bearish-24300-key-level-to-watch-...
06 Mar 2026
PhonePe’s merchant network hits 47 million businesses; DRHP reveals diversified monetisation
phonepes-merchant-network-hits-47-million-businesses-drhp-re...
06 Mar 2026
Curefoods chases multiple ₹300 crore premium and niche brands as it widens food portfolio
curefoods-chases-multiple-rs300-crore-premium-and-niche-bran...
06 Mar 2026
pre ipo advisory services in India
  • GST No: 07AAHCB7068H2ZF

India IPO is a leading Indian business services platform that helps firms and companies to launch their initial public offerings (IPOs) in order to raise essential capital for growth and expansion while adding value & fueling the nation’s immense potential and future opportunities.

Follow us:

Facebook Twitter LinkedIn Instagram YouTube

Quick Links

  • Home
  • Blogs
  • Consultant
  • Youtube Videos
  • News
  • Contact Us
  • Career

Contact Information:

  • Corporate Office: 808, 8th Floor, D-Mall, Netaji Subhash Place, Pitampura, Delhi-110034
  • Regional Office: Office No. 601, Shagun Insignia, Ulwe, Sector-19, Navi Mumbai- 410206
  • Email: info@indiaipo.in
  • Mobile: +91-74283-37280, +91-96509-82781
  • Disclaimer  |
  • Privacy & Policy  |
  • Terms & Conditions  

Copyright © All rights reserved by - Bmarkt Tecamat Private Limited